12,900 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Harvey Capital Management Inc.

Harvey Capital Management Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,900 shares of the company's stock, valued at approximately $354,000.

Other institutional investors have also recently made changes to their positions in the company. Values First Advisors Inc. purchased a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at $57,000. CWM LLC boosted its stake in shares of BridgeBio Pharma by 132.9% in the 3rd quarter. CWM LLC now owns 3,442 shares of the company's stock valued at $88,000 after purchasing an additional 1,964 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in shares of BridgeBio Pharma by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after purchasing an additional 1,645 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of BridgeBio Pharma by 17.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock valued at $135,000 after purchasing an additional 801 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $181,000. Institutional investors own 99.85% of the company's stock.

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock traded up $3.34 during trading on Friday, hitting $34.90. The company's stock had a trading volume of 3,372,917 shares, compared to its average volume of 3,171,595. The company has a fifty day simple moving average of $31.15 and a two-hundred day simple moving average of $27.58. The company has a market capitalization of $6.60 billion, a PE ratio of -14.48 and a beta of 1.07. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $41.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. HC Wainwright reissued a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday. Evercore ISI increased their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research report on Monday, December 23rd. Finally, Scotiabank increased their price target on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a "sector outperform" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.08.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the sale, the insider now directly owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. This trade represents a 12.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the sale, the chief financial officer now owns 93,758 shares of the company's stock, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,492,093 shares of company stock worth $122,029,004. 24.66% of the stock is owned by corporate insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.